1. Introduction
===============

Ovarian cancer is one of the common malignant tumors of the female reproductive system, with an incidence rate that ranks it as the third most common gynecologic cancer behind cervical and uterine cancers. However, ovarian cancer is the gynecologic malignancy with the highest mortality rate. Clarifying the methods of timely detection, diagnosis, and prevention of ovarian cancer to decrease its incidence and mortality rate has been the key goal of gynecologic oncologists for decades. With the development of precision medicine, mutations in the breast cancer susceptibility genes (BRCAs) including *BRCA1* and *BRCA2*, have come to be known to be related to the pathogenesis of hereditary ovarian and breast cancer. Approximately 30% of hereditary ovarian and/or breast cancer occurrences are associated with *BRCA1/2* gene mutations.^\[[@R1],[@R2]\]^ To date, there are thousands of mutation positions that have been discovered in the *BRCA1/2* genes. In the general population, the risk of breast cancer is about 10%, and for ovarian cancer it is about 1%, whereas the risk of breast or ovarian cancer in women with *BRCA* missense mutations exceeds 80%.^\[[@R1],[@R2]\]^ Therefore, it is necessary to conduct early screening and clinical interventions in these high-risk populations. Herein, we report the case of a woman diagnosed with ovarian and breast cancer, with a mutation in the *BRCA1* gene that may be a new pathogenic mutation.

2. Case report
==============

A 48-year-old woman, gravida 3, para 1, had been postmenopausal for 2 years. At the age of 42 she underwent a left breast radical mastectomy due to breast cancer on the left side, without postoperative adjuvant therapy. She maintained regular outpatient follow-ups. In 2016, she presented and was admitted to our hospital due to complaints of "bloating for more than 1 month and progressive worsening." Transvaginal color Doppler ultrasound detected a 16.1 × 11.4 × 15.6 cm mixed cystic and solid pelvic mass with an irregular shape and a blood flow signal resistive index = 0.64 (Fig. [1](#F1){ref-type="fig"}A). An abdomen and pelvis computed tomography (CT) scan revealed irregularly shaped cystic and solid masses in the bilateral ovaries and fallopian tubes the left mass measured approximately 8.1 × 5.2 × 15.6 cm and was predominantly solid. The right mass measured approximately 10.3 × 8.2 × 9.8 cm and was predominantly cystic (Fig. [1](#F1){ref-type="fig"}B). Enhanced CT scanning demonstrated uneven enhancement, with an "ovarian vascular pedicle" on each side (Fig. [1](#F1){ref-type="fig"}C). The serum cancer antigen 125 level was 3952.6 U/mL. The patient underwent 3 separate paracentesis procedures, with a total of 6200 mL of light yellow ascites removed. The ascitic fluid was positive for tumor cells. At that time, a malignant tumor was suspected, possibly originating from the reproductive system. On the recto-vaginal and abdominal examinations, huge cystic-solid masses in the pelvis and abdomen, suspected severe intestinal adhesions, and extensive hard nodular lesions on the sacroiliac ligaments were detected. Three gynecologic oncology specialists and imaging specialists evaluated the CT scan images and the findings scored 10(10/23) according to the Bristow standard, which indicated that the predictive index score ≥4 would be helpful to more accurately identify patients with advanced epithelial ovarian carcinoma that were unlikely to undergo optimal primary cytoreductive surgery.^\[[@R3]\]^ They suggested that such patients would not achieve satisfactory results from tumor reduction surgery, and instead, preoperative adjuvant chemotherapy should be recommended. For our patient, a preoperative paclitaxel--cisplatin combined regimen (paclitaxel 175 mg/m^2^ intravenous guttae (ivgtt) + cisplatin 75 mg/m^2^ ivgtt, at intervals of 3 weeks) was administered for a total of 3 courses. In late 2016, she underwent a laparoscopic hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and pelvic and para-aortic lymph node dissection. The surgical outcome was satisfactory with no residual cancer foci. The postoperative biopsy results demonstrated high-grade serous adenocarcinoma of the bilateral ovaries that also involved the bilateral fallopian tubes and bilateral pelvic walls, but there was no lymph node involvement (Fig. [2](#F2){ref-type="fig"}). Subsequently, the patient received a postoperative paclitaxel--cisplatin regimen that included carboplatin (paclitaxel 175 mg/m^2^ ivgtt + cisplatin 75 mg/m^2^ ivgtt/carboplatin 400 mg/m^2^ ivgtt, at intervals of 3 weeks) for 8 courses. The chemotherapy was completed in mid-2017 and the patient has continued close follow-up to this point.

![(A) Preoperative transvaginal ultrasound (the lesions were marked by red arrow heads), (B) preoperative CT (the lesions were marked by red arrow heads), and (C) preoperative enhanced CT (the lesions were marked by red arrow heads). CT = computed tomography.](medi-97-e12371-g001){#F1}

![Ovarian high-grade serous adenocarcinoma (HE ×100).](medi-97-e12371-g002){#F2}

During chemotherapy she suffered from severe vomiting, fatigue, and moderate bone marrow suppression. Her symptoms were significantly relieved after symptomatic support treatment. Her serum cancer antigen 125 decreased significantly to 10 U/mL after 3 cycles of preoperative chemotherapy, and it declined progressively during the postoperative chemotherapy finally reaching 5.1 U/mL at the end of the chemotherapy course. Follow-up lung and pelvic CT scans were performed after 3 and 8 courses of postoperative chemotherapy, respectively. Both results showed that the patient was in a state of complete remission (CR).

After 3 courses of postoperative chemotherapy, our patient\'s blood was subjected to *BRCA* testing (Sanger sequencing, Shenzhen BGI Clinical Laboratory Center). The results demonstrated a frame shift mutation of the *BRCA1* gene c.3487_3488insA (p.Thr1163AsnfsX2). This patient had a family history of malignancy, as her sister was diagnosed with breast cancer at the age of 41 (Fig. [3](#F3){ref-type="fig"}). Further Sanger sequencing confirmed that the sister had the same *BRCA1* gene mutation as our patient. In mid-2016, the sister underwent laparoscopic hysterectomy with bilateral salpingo-oophorectomy at our hospital. No malignant tumors were found on biopsy. She was discharged 2 days later and had all normal follow-up evaluations. Their mother was diagnosed with ovarian cancer at the age of 57, which was her ultimate cause of death, and their father has gastric cancer (Fig. [3](#F3){ref-type="fig"}).

![Family tree of the patient. BC = breast cancer, GC = gastric cancer, OC = ovarian cancer.](medi-97-e12371-g003){#F3}

3. Discussion
=============

BRCAs are important tumor suppressor genes and tumor susceptibility genes, comprising *BRCA1* and *BRCA2*, which play important roles in the homologous recombination mechanism in DNA repair. Germ line *BRCA1/2* mutations significantly increase the risk of breast, ovarian, and other cancers in women. According to the classification systems from the National Cancer Institute (NCI),^\[[@R4]\]^ the American College of Medical Genetics and Genomics (ACMG),^\[[@R5]\]^ and the Evidence-based Network Interpretation of Germ line Mutant Alleles (ENIGMA),^\[[@R6]\]^ the *BRCA* gene mutations are divided into the following 5 grades, listed here with risks from highest to lowest: pathogenic (grade 5, pathogenic probability \> 0.99), possible pathogenic (grade 4, pathogenic probability 0.95--0.99), meaning unknown (grade 3, pathogenic probability 0.05--0.949), possible benign (grade 2, pathogenic probability 0.001--0.049), and benign (grade 1, pathogenic probability \<0.001). Considering that 2 members of that family (the patient with breast cancer and ovarian cancer, and her sister with breast cancer) had the genetic mutation at the same site, this novel frame shift mutation in the *BRCA1* gene may be a grade 5 pathogenic mutation. Thus, women with genetic mutations at this site are extremely likely to have the highest risk of breast and ovarian cancers.

*BRCA* mutation classification is based on the published data in Europe and the United States. In 2017, for the first time and based on a large sample, Wu et al reported that the *BRCA* mutation rate in patients with ovarian cancer in China was 27.8%, of which 20.8% were *BRCA1* mutations and 7.6% were *BRCA2* mutations.^\[[@R7]\]^ However, China has not yet established a large database of gene mutations. Whether the mutation sites are different from those in the European and American populations needs to be determined from clinical and basic research combined with patient and family histories. Continuing discoveries and studies of new pathogenic gene mutation sites and types could provide important guidance for screening, early diagnosis, intervention, and treatment of ovarian cancer in China. In this report, *BRCA* gene tests found a *BRCA1* gene frame shift mutation c.3487_3488insA (p.Thr 1163AsnfsX2) that resulted in an encoding length of 1163 amino acids, which represented a truncated polypeptide chain since the normal *BRCA1* gene encodes 1863 amino acids. Until now, there has been no report on the functional studies and clinical significance of this mutation, and its frequency is 0 in the One Thousand Genomes Project. This mutation is suspected to be pathogenic. Moreover, our ovarian cancer patient had a history of breast cancer and a significant family history of malignant tumors. Therefore, clinically it is recommended to escalate the frame shift mutation of the *BRCA1* gene c.3487_3488insA (p. Thr1163AsnfsX2) to a pathogenic grade. This is a newly discovered pathogenic mutation in the Chinese population and imparts great value to the screening and early diagnosis of ovarian/breast cancer. However, the new mutation has been identified only in 2 cases in this family, because the patient\'s mother died of ovarian cancer many years ago, and therefore, testing of the mother could not be performed. In addition, the protein function associated with this mutation has yet to be completed.

4. Conclusion
=============

The c.3487_3488insA (p.Thr1163AsnfsX2) *BRCA1* mutation may be a new pathogenic mutation in the *BRCA1* gene. Its association with breast and ovarian cancers needs to be further verified through more case studies. Moreover, mutant protein function research in both human cells and animal models are also needed.
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